#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Tumorlet and antifibrotic treatment


Authors: J. Krynská
Authors‘ workplace: Branislavova 1415/1, 266 01 Beroun
Published in: Reviz. posud. Lék., 23, 2020, č. 3-4, s. 79-82
Category: Original Articles, Review Articles, Case Reports

Overview

Pulmonary fibrotic processes are very inhomogeneous etiologies, destructive changes in lung tissue can occur even in the rare occurrence of hyperplasia of neuroendocrine cells in the lung parenchyma, considered as precancerous. Treatments are ambiguous, often only monitoring is recommended, some studies refer to the concomitant production of profibrotic factors VEGF and TGF-β1 and consider the action of antifibrotics.

Keywords:

diffuse idiopathic neuroendocrine cell hyperplasia – DIPNECH – preneoplasia pulmonary carcinoid tumors – tumorlet – antifibrotic therapy – nintedanib


Sources

1. Ping, He., Xia, Gu., Qinian, Wu., Yunen, Lin., Yingying, Gu., Jianxing, He.: Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis. Journal of Thoracic Disease, December 2012.

2. Wirtschafter E., Walts, A. E., Liu, S. T., Marchevsky, A. M.: Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia of the Lung (DIPNECH): Current Best Evidence. National Library od Medicine, Oct. 2015.

3. Myint, Z. W., McCormick, J., Chauhan A., Behrens, E., Lowell, B. A.: Management of Diffuse Idiopathic Pulmonary Neuro-endocrine Cell Hyperplasia: Review and a Single Center Expe-rience. Cureus, September 13, 2019. 

Labels
Medical assessment Occupational medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#